

## DAFTAR PUSTAKA

- Adejumo, O. A., Okaka, E. I., Okwuonu, C. G., Iyawe, I. O., & Odujoko, O. O. (2016). Serum C-reactive protein levels in pre-dialysis chronic kidney disease patients in southern Nigeria. *Ghana medical journal*, 50(1), 31–38.
- Akchurin, O. M., & Kaskel, F. (2015). *Update on Inflammation in Chronic Kidney Disease. Blood Purification*, 39(1-3), 84–92.
- Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). *Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology*, 12(12), 2032–2045. doi:10.2215/cjn.11491116
- Amdur, R., Feldman, H., Gupta, J., Yang, W., Kanetsky, P., Shlipak, M., Rahman, M., Lash, J., Townsend, R., Ojo, A., Roy-Chaudhury, A., Go, A., Joffe, M., He, J., Balakrishnan, V., Kimmel, P., Kusek, J. and Raj, D. (2016). Inflammation and Progression of CKD: The CRIC Study. *Clinical Journal of the American Society of Nephrology*, 11(9), pp.1546-1556.
- American Heart Association. (2017). *Monitor Your Blood Pressure*. [online] diakses dari : <https://www.heart.org/en/health-topics/high-blood-pressure/the-facts-about-high-blood-pressure> [diakses pada 10 Mei 2019].
- Assadpour Piranfar M. (2014). The Correlation between High-Sensitivity C-Reactive Protein (hsCRP) Serum Levels and Severity of Coronary Atherosclerosis. *International cardiovascular research journal*, 8(1), 6–8.
- Bassuk, S., Rifai, N. and Ridker, P. (2004). High-sensitivity C-reactive protein. *Current Problems in Cardiology*, 29(8), pp.439-493.
- Biasucci, L. M. (2005). *Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina. Heart*, 91(5), 670–671. doi:10.1136/hrt.2004.036509
- Carrero, J., Hecking, M., Chesnaye, N and Jager, K. (2018). Sex and Gender Disparities in The Epidemiology and Outcomes of Chronic Kidney Disease. *Nature Reviews Nephrology*, 14 : 151–164
- Centers for Disease Control and Prevention. (2019). National Chronic Kidney Disease [online]diakses dari: [https://www.cdc.gov/diabetes/pubs/pdf/kidney\\_factsheet.pdf](https://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf) [diakses pada 4 Mei 2019].
- Cobo, G., Hecking, M., Port, F. K., Exner, I., Lindholm, B., Stenvinkel, P., & Carrero, J. J. (2016). *Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clinical Science*, 130(14) : 1147–1163
- Cravedi, P., & Remuzzi, G. (2013). Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. *British journal of clinical pharmacology*, 76(4), 516–523.

- Denic, A., Glasscock, R. J., & Rule, A. D. (2016). Structural and Functional Changes With the Aging Kidney. *Advances in Chronic Kidney Disease*, 23(1) : 19–28.
- Di Raimondo, D., Tuttolomondo, A., Butta, C., Miceli, S., Licata, G., & Pinto, A. (2012). *Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation*. *Current Pharmaceutical Design*, 18(28), 43854413. doi:10.2174/138161212802481282
- Falodia, J., & Singla, M. K. (2012). CKD epidemiology and risk factors. *Clinical Queries: Nephrology*, 1(4) : 249–252.
- Fanelli, C., dan Zatz, R. (2011). Linking Oxidative Stress, the Renin-Angiotensin System, and Hypertension. *AHA*, 57(3), 373–374.
- Garland, J. (2014). *Elevated body mass index as a risk factor for chronic kidney disease: current perspectives*. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 347. doi:10.2147/dms0.s46674
- Global Burden of Disease. (2019). GBD Compare Health Data. [online] diakses dari: <https://vizhub.healthdata.org/gbd-compare/> [diakses pada 17 Maret 2019].
- Güliz KozdağACE, Gökhan ErtaşBCDEF, Teoman KılıçC, Eser AcarB, Ayşen AğırDF, Tayfun ŞahinF, Metin ÇetinD, Ulaş BildiriciDF, Dilek Ural (2010) Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure. *Med Sci Monit*. 16(3),160
- Gupta, J., Mitra, N., Kanetsky, P. A., Devaney, J., Wing, M. R., ... Reilly, M. (2012). *Association between Albuminuria, Kidney Function, and Inflammatory Biomarker Profile in CKD in CRIC*. *Clinical Journal of the American Society of Nephrology*, 7(12), 1938–1946. doi:10.2215/cjn.03500412
- Hager, M. R., Narla, A. D., & Tannock, L. R. (2016). Dyslipidemia in patients with chronic kidney disease. *Reviews in Endocrine and Metabolic Disorders*, 18(1), 29–40.
- Hall, M. E., Wang, W., Okhomin, V., Agarwal, M., Hall, J. E., Dreisbach, A. W., Young, B. A. (2016). *Cigarette Smoking and Chronic Kidney Disease in African Americans in the Jackson Heart Study*. *Journal of the American Heart Association*, 5(6), 3280.
- Harrison, 2012. *Principle of Internal Medicine*, 18<sup>th</sup> ed, Mc-Graw Hill, pp. 2308-2309.
- Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Locatelli, F. (2019). *Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials*. *The Lancet Diabetes & Endocrinology*.
- Heidari B. (2013). C-reactive protein and other markers of inflammation in hemodialysis patients. *Caspian journal of internal medicine*, 4(1): 611–616.
- Hildebrand, A. and Garg, A. (2013). Blood pressure targets in chronic kidney disease. *Canadian Medical Association Journal*, 185(11), pp.941-942.

- Horowitz, B., Miskulin, D., & Zager, P. (2015). *Epidemiology of Hypertension in CKD. Advances in Chronic Kidney Disease*, 22(2), 88–95.
- Hung, A. M., Ellis, C. D., Shintani, A., Booker, C., & Ikizler, T. A. (2011). *IL-1 Receptor Antagonist Reduces Inflammation in Hemodialysis Patients. Journal of the American Society of Nephrology*, 22(3): 437–442.
- Impellizzeri, D., Esposito, E., Attley, J. dan Cuzzocrea, S. (2014). Targeting inflammation: New therapeutic approaches in chronic kidney disease (CKD). *Pharmacological Research*, 81, pp.91-102.
- Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. and Yang, C. (2013). Chronic kidney disease: global dimension and perspectives. *The Lancet*, 382(9888), pp.260-272.
- Jofre, R., Rodriguez-Benitez, P., Lopez-Gomez, J. M., & Perez-Garcia, R. (2006). *Inflammatory Syndrome in Patients on Hemodialysis. Journal of the American Society of Nephrology*, 17(12) :274–S280
- Joynt, K. E., Gattis, W. A., Hasselblad, V., Fuzaylov, S. Y., Serebruany, V. L., Gurbel, P. A., ... O'Connor, C. M. (2004). *Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. The American Journal of Cardiology*, 93(6), 783–785. doi:10.1016/j.amjcard.2003.12.010
- Katzung, B., Masters, S. dan Trevor, A. (2012). *Farmakologi dasar dan klinik*. 12th ed. Jakarta: EGC, pp. 173-193.
- Katzung, B.G., Masters, S.B. dan Trevor, A.J. (2013). *Pharmacology Examination & Board Review*. 10<sup>th</sup> ed. Jakarta : EGC, pp.143-145
- Kazancioğlu, R., 2013. Risk factors for chronic kidney disease: an update. *Kidney International Supplements*, 3(4), pp.368-371.
- Kementerian Kesehatan RI Badan Penelitian dan Pengembangan Kesehatan. (2018). Hasil Utama Riskesdas 2018. [online] diakses dari: <http://www.depkes.go.id/resources/download/info-terkini/hasil-riskesdas-2018.pdf> [diakses pada 4 April 2019].
- Kidney Disease Improving Global Outcomes. (2013). *Clinical Practice Guideline for the Evaluation and Management*. [online] diakses dari: [https://kdigo.org/wp-content/uploads/2017/02/KDIGO\\_2012\\_CKD\\_GL.pdf](https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf) [diakses pada 5 April 2019].
- Kidney Health Australia. (2015). *Chronic Kidney Disease (CKD) Management in General Practice*. [online] diakses dari: [https://kidney.org.au/cms\\_uploads/docs/ckd-management-in-gp-handbook-3rd-edition.pdf](https://kidney.org.au/cms_uploads/docs/ckd-management-in-gp-handbook-3rd-edition.pdf) [diakses pada 4 Maret 2019].

- Kovesdy, C., Furth, S. dan Zoccali, C., 2017. Obesity and Kidney Disease. *Canadian Journal of Kidney Health and Disease*, 4.
- Ku, E., Lee, B. J., Wei, J., & Weir, M. R. (2019). *Hypertension in CKD: Core Curriculum 2019*. *American Journal of Kidney Diseases*. doi:10.1053/j.ajkd.2018.12.044
- Kumar, S. dan Shbharani, B. (2015). Comparative Study of Hscrp in Chronic Kidney Disease. *Journal of Pharmacy*, 5(7), pp 8-12.
- Laveti, D., Kumar, M., Hemalatha, R., Sistla, R., Naidu, V., Talla, V., Verma, V., Kaur, N. and Nagpal, R. (2013). Anti-Inflammatory Treatments for Chronic Diseases: A Review. *Inflammation & Allergy-Drug Targets*, 12(5), pp.349-361.
- Leonard, S. (2011). *Pathophysiology of Heart Disease*. 5th ed. Philadelphia: Wolters Kluwer, pp. 394-197.
- Levin, A., Hemmelgarn, B., Culleton, B., Tobe, S., McFarlane, P., Ruzicka, M., Canadian Society of Nephrology (2008). Guidelines for the management of chronic kidney disease. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, 179(11), 1154–1162. Leonberg-Yoo, A. dan Rudnick, M., 2017. Tobacco Use: A Chronic Kidney Disease Accelerant. *American Journal of Nephrology*, 46(4), pp.257-259.
- LI, E., Heran, B. and Wright, J. (2014). Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. *Cochrane Database of Systematic Reviews*.
- Lima, E., Batista, D., Martins, E. dan Hueb, W., 2018. Chronic Kidney Disease and Coronary Artery Disease. *Advances in Nephropathy*.
- López-Novoa, J., Martínez-Salgado, C., Rodríguez-Peña, A. and Hernández, F. (2010). Common pathophysiological mechanisms of chronic kidney disease: Therapeutic perspectives. *Pharmacology & Therapeutics*, 128(1), pp.61-81.
- Lu, J. L., Molnar, M. Z., Naseer, A., Mikkelsen, M. K., Kalantar-Zadeh, K., & Kovesdy, C. P. (2015). Association of age and BMI with kidney function and mortality: a cohort study. *The Lancet Diabetes & Endocrinology*, 3(9) : 704–714
- Machowska, A., Carrero, J., Lindholm, B. and Stenvinkel, P. (2016). Therapeutics targeting persistent inflammation in chronic kidney disease. *Translational Research*, 167(1), pp.204-213.
- Masoli, J., Delgado, J., Bowman, K., Strain, W. D., Henley, W., & Melzer, D. (2019). Association of blood pressure with clinical outcomes in older adults with chronic kidney disease. *Age and ageing*, 48(3), 380–387.
- McMahon, G., Preis, S., Hwang, S. and Fox, C. (2014). Mid-Adulthood Risk Factor Profiles for CKD. *Journal of the American Society of Nephrology*, 25(11), pp.2633-2641.

- Menon, V., Gul, A., & Sarnak, M. J. (2005). *Cardiovascular risk factors in chronic kidney disease. Kidney International*, 68(4) : 1413–1418.
- Mihai, S., Codrici, E., Popescu, I., Enciu, A., Albulescu, L., Necula, L., Mambet, C., Anton, G. and Tanase, C. (2018). Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. *Journal of Immunology Research*, 2018, pp.1-16.
- Mishima, E., Haruna, Y. and Arima, H. (2019). Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials. *Hypertension Research*, 42(4), pp.469-482.
- Mittal, M., Siddiqui, M., Tran, K., Reddy, S. and Malik, A. (2014). Reactive Oxygen Species in Inflammation and Tissue Injury. *Antioxidants & Redox Signaling*, 20(7), pp.1126-1167.
- Molnar, M., Kalantar-Zadeh, K., Lott, E., Lu, J., Malakauskas, S., Ma, J., Quarles, D. and Kovesdy, C. (2014). Angiotensin-Converting Enzyme Inhibitor, Angiotensin Receptor Blocker Use, and Mortality in Patients With Chronic Kidney Disease. *Journal of the American College of Cardiology*, 63(7), pp.650-658.
- Moore, C. (2011). *Clinical Practice Recommendations for Primary Care Physicians and Healthcare Providers*. [online] Asn-online.org. Available at: [https://www.asn-online.org/education/training/fellows/HFHS\\_CKD\\_V6.pdf](https://www.asn-online.org/education/training/fellows/HFHS_CKD_V6.pdf) [Accessed 16 May 2019].
- Nagasawa, Y., Yamamoto, R., Rakugi, H., & Isaka, Y. (2011). *Cigarette smoking and chronic kidney diseases. Hypertension Research*, 35(3), 261–265.
- Nagy, V. (2017). Klasszikus vérnyomáscsökkentők: diuretikumok. *Orvosi Hetilap*, 158(11), pp.403-408.
- National Kidney Foundation. (2019). *About Chronic Kidney Disease*. [online] diakses dari : <https://www.kidney.org/atoz/content/about-chronic-kidney-disease#causes> [Diakses pada 18 April 2019].
- National Lybrary of Medicine (2017). *C-reactive protein: MedlinePlus Medical Encyclopedia*. [online] diakses dari: <https://medlineplus.gov/ency/article/003356.htm> [diakses pada 1 April 2019].
- Neugarten, J. dan Golestaneh, L., 2013. Gender and the Prevalence and Progression of Renal Disease. *Advances in Chronic Kidney Disease*, 20(5) : .390-395.
- Pais, P., Kamath, D., Xavier, D. dan Sigamani, A. (2015). High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective. *Indian Journal of Medical Research*, 142(3), p.261.

- Palmas, W., Ma, S., Psaty, B., Goffjr, D., Darwin, C., & Barr, R. (2007). *Antihypertensive Medications and C-Reactive Protein in the Multi-Ethnic Study of Atherosclerosis*. *American Journal of Hypertension*, 20(3), 233–241
- Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. (2015). *Pedoman Tatalaksana Hipertensi Pada Penyakit Kardiovaskular*. [online] diakses dari: [http://www.inaheart.org/upload/file/Pedoman\\_TataLaksana\\_hipertensi\\_pada\\_penyakit\\_Kardiovaskular\\_2015.pdf](http://www.inaheart.org/upload/file/Pedoman_TataLaksana_hipertensi_pada_penyakit_Kardiovaskular_2015.pdf) [diakses pada 2 Mei 2019].
- Pusat Data dan Informasi Kementerian Kesehatan RI. (2017). *Situasi Penyakit Ginjal Kronis*. [online] diakses dari: <http://www.depkes.go.id/download.php?file=download/pusdatin/infodatin/infodatin%20ginjal%202017.pdf> [diakses pada 2 Maret 2019].
- Simões e Silva, A. and Teixeira, M. (2016). ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. *Pharmacological Research*, 107, pp.154-162.
- Staplin, N., Haynes, R., Herrington, W. G., Reith, C., Cass, A., Fellström, B., Levin, A. (2016). *Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)*. *American Journal of Kidney Diseases*, 68(3), 371–380.
- Sun, Y.-M., Su, Y., Li, J., & Wang, L.-F. (2013). *Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy*. *Biochemical and Biophysical Research Communications*, 433(4), 359–361.
- Tbahriti, H. F., Meknassi, D., Moussaoui, R., Messaoudi, A., Zemour, L., Kaddous, A., Mekki, K. (2013). Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines. *World journal of nephrology*, 2(2), 31–37.
- Thaha, M., Kadariswantiningsih, I. dan Empitu, M. (2019). Association of High Blood Pressure with Elevated Oxidative Stress, Inflammatory Marker and Albuminuria in Chronic Kidney Disease Patients. *Journal of Medicine*, 20(1), pp.12-18
- Tonelli, M., Wiebe, N., Guthrie, B., James, M. T., Quan, H., Fortin, M., ... Hemmelgarn, B. R. (2015). *Comorbidity as a driver of adverse outcomes in people with chronic kidney disease*. *Kidney International*, 88(4): 859–866.
- Tsai, W.-C., Wu, H.-Y., Peng, Y.-S., Ko, M.-J., Wu, M.-S., Hung, K.-Y., ... Chien, K.-L. (2016). *Risk Factors for Development and Progression of Chronic Kidney Disease*. *Medicine*, 95(11): 3013.
- Tsimihodimos, V. (2011). *Dyslipidemia Associated with Chronic Kidney Disease*. *The Open Cardiovascular Medicine Journal*, 5(1), 41–48. doi:10.2174/1874192401105010041
- Tucker, P., Scanlan, A. and Dalbo, V. (2019). *Chronic Kidney Disease Influences Multiple Systems: Describing the Relationship between Oxidative Stress, Inflammation, Kidney Damage, and Concomitant Disease..*

- Wong, E. (2012). *Chronic kidney disease (CKD) | McMaster Pathophysiology Review*. [online] Pathophys.org. diakses dari : <http://www.pathophys.org/ckd/> [diakses pada 16 Maret 2019].
- Xie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., Zhao, N., Liu, L., Lv, J., Zhang, H. and Wang, H. (2016). Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. *American Journal of Kidney Diseases*, 67(5), pp.728-741.
- Y Putri, Alisia & Thaha, Mochammad. (2014). Role of oxidative stress on chronic kidney disease progression. *Acta medica Indonesiana*. 46. 244-52.
- Yousuf, O., Mohanty, B., Martin, S., Joshi, P., Blaha, M., Nasir, K., Blumenthal, R. and Budoff, M. (2013). High-Sensitivity C-Reactive Protein and Cardiovascular Disease. *Journal of the American College of Cardiology*, 62(5), pp.397-408.
- Zhang, F., Liu, H., Liu, D., Liu, Y., Li, H., Tan, X., ... Zhang, H. (2017). *Effects of RAAS Inhibitors in Patients with Kidney Disease*. *Current Hypertension Reports*, 19(9). doi:10.1007/s11906-017-0771-9